Mirikizumab: A promising breakthrough in Crohn's disease treatment
Abstract Introduction Crohn's disease (CD) is a chronic, progressive inflammatory bowel disorder characterized by persistent inflammation and noncontiguous “skip lesions” throughout the gastrointestinal tract. With a prevalence of 100–300 cases per 100,000 individuals, CD is most common in West...
Saved in:
| Main Authors: | Muaaz Aslam, Mohammad Haris Ali, Hamza Irfan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-08-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.2294 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mirikizumab Pharmacokinetics and Exposure‐Response in Patients With Moderately‐To‐Severely Active Crohn's Disease: Results From Two Randomized Studies
by: Laiyi Chua, et al.
Published: (2025-08-01) -
Efficacy and safety of Mirikizumab for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials
by: Mohamed A. Abu Elainein, et al.
Published: (2025-04-01) -
SEVERE FORM OF CROHN’S DISEASE IN COMBINATION WITH AUTOIMMUNE LIVER DISEASE
by: G. I. Sinenchenko, et al.
Published: (2018-06-01) -
IgA Vasculitis Induced by Ustekinumab During Treatment for Crohn’s Disease: A Case Report
by: Yu Okada, et al.
Published: (2025-08-01) -
Placebo-Controlled Trials in the Management of Crohn’s Disease: An Umbrella Review of Meta-Analyses
by: Richard Silva, et al.
Published: (2025-01-01)